Neuroprotection in experimental stroke with targeted neurotrophins

被引：101

作者：

Wu D. ^{[1
,2
]}

机构：

[1] Department of Radiology, Wayne State University, Children's Hospital of Michigan, Detroit

[2] Children's Hospital of Michigan, PET Center, Detroit, MI 48201

来源：

NeuroRX | 2005年 / 2卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Blood-brain barrier; Drug targeting; Ischemic stroke; Neuroprotection; Neurotrophins; Transferrin receptor;

D O I：

10.1602/neurorx.2.1.120

中图分类号：

学科分类号：

摘要：

More than 30 neurotrophins have been identified, and many of them have neuroprotective effects in brain ischemia or injury. However, all the clinical trials with several neurotrophins for the treatment of acute ischemic stroke or neurodegenerative diseases have failed so far, primarily because of their poor blood-brain barrier (BBB) permeability. This article is an overview of recent progress in the research focused on BBB targeted neurotrophins using a chimeric peptide approach, in which antitransferrin receptor antibody was used as a BBB delivery vector, and neurotrophin peptide was conjugated to the antibody via the avidin/biotin technology. Vasoactive intestinal peptide was the first model chimeric peptide to show an enhanced CNS effect after noninvasive peripheral administration. Brain-derived neurotrophic factor (BDNF) chimeric peptide was neuroprotective in rats subjected to transient forebrain ischemia, permanent focal ischemia, or transient focal ischemia. Delayed treatments with the BDNF chimeric peptide showed an effective time window of 1-2 h after ischemia. Basic FGF chimeric peptide was highly effective in the reduction of infarct volume in the rat model of permanent focal ischemia, with lowest effective dose of 1 μg per rat. Future studies in this exciting area include genetically engineered fusion proteins or humanized antibodies for BBB drug targeting with less immunogenicity and reduced working burden in the chemical conjugation, the use of antihuman insulin receptor antibody for higher BBB delivery efficiency, and combination therapies using chimeric neurotrophins plus other neuroprotectants to achieve additive or synergistic effects.

引用

页码：120 / 128

页数：8

共 67 条

[1]

Broderick J.P., William M., Feinberg Lecture: Stroke therapy in the year 2025. Burden, breakthroughs, and barriers to progress, Stroke, 35, pp. 205-211, (2004)

[2]

Fieschi C., Argentino C., Lenzi G.L., Sacchetti M.L., Toni D., Bozzao L., Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours, J Neurol Sci, 91, pp. 311-322, (1989)

[3]

Tissue plasminogen activator for acute ischemic stroke, N Engl J Med, 333, pp. 1581-1587, (1995)

[4]

Furlan A., Higashida R., Wechsler L., Gent M., Rowley H., Kase C., Et al., Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in acute ischemic cerebral thromboembolism, JAMA, 282, pp. 2003-2011, (1999)

[5]

Ford G.A., Bryant C.A., Mangoni A.A., Jackson S.H.D., Stroke, dementia, and drug delivery, Br J Clin Pharmacol, 57, pp. 15-26, (2004)

[6]

Hacke W., Brott T., Caplan L.R., Meier D., Fieschi C., Von Kummer R., Et al., Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience, Neurology, 53, SUPPL., (1999)

[7]

Hinkle J.L., Bowman L., Neuroprotection for ischemic stroke, J Neurosci Nurs, 35, pp. 114-118, (2003)

[8]

Ovbiagele B., Kidwell C.S., Starkman S., Saver J.L., Neuroprotective agents for the treatment of acute ischemic stroke, Curr Neurol Neurosci Rep, 3, pp. 9-20, (2003)

[9]

Wahlgren N.G., Ahmed N., Neuroprotection in cerebral ischemia: Facts and fancies - The need for new approaches, Cerebrovascular Dis, 17, 1 SUPPL., pp. 153-166, (2004)

[10]

Menzies S.A., Betz A.L., Hoff J.T., Contributions of ions and albumin to the formation and resolution of ischemic brain edema, J Neurosurg, 78, pp. 257-266, (1993)

← 1 2 3 4 5 6 7 →